SCHEMBL2947157

SCHEMBL2947157

CCCCOc1ccc(C(CC(=O)O)c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.57
FFAR1 O14842 8/20 0.55
PPARG P37231 2/20 0.53
PTGES O14684 1/20 0.53
ALOX5 P09917 1/20 0.53
PPARA Q07869 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.50
MMP9 P14780 1/20 0.48
MMP8 P22894 1/20 0.48
MMP13 P45452 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HTT P42858 1/20 0.45
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
LTB4R2 Q9NPC1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13236752 0.89 FAAH (0.53) FAAHFFAR1PPARGPTGESALOX5
SCHEMBL2948038 0.88 FFAR1 (0.57) FAAHFFAR1PPARGPPARASMN1; SMN2
SCHEMBL3521686 0.86 FFAR1 (0.60) FAAHFFAR1PPARGPTGESALOX5
SCHEMBL2946236 0.84 FFAR1 (0.53) FAAHFFAR1SMN1; SMN2MMP9MMP8
SCHEMBL2948148 0.84 FFAR1 (0.68) FAAHFFAR1SMN1; SMN2MMP9MMP8
SCHEMBL3524392 0.81 FFAR1 (0.53) FAAHFFAR1PPARGPTGESALOX5
SCHEMBL2941508 0.81 MMP9 (0.65) FFAR1SMN1; SMN2MMP9MMP8MMP13
Hydrochloric Acid SCHEMBL9293074 0.81 CACNA2D1 (0.56) FFAR1SMN1; SMN2ALDH1A1
SCHEMBL2946249 0.80 MMP9 (0.54) FFAR1SMN1; SMN2MMP9MMP8MMP13
SCHEMBL2939695 0.80 MMP9 (0.67) FAAHFFAR1SMN1; SMN2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US claimed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US claimed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176912-A1 GPR40 AGONISTS GPR119, GPR65, GPR55 FAAH 600/4885FFAR1 8/4885PPARG 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.